Trial Profile
A Neuroimaging clinical study of ASN120290 in progressive supranuclear palsy (PSP)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2019
Price :
$35
*
At a glance
- Drugs ASN 90 (Primary)
- Indications Progressive supranuclear palsy
- Focus Therapeutic Use
- 17 Jan 2019 According to an Asceneuron media release, the results of this trial will guide dose selection for an efficacy trial in progressive supranuclear palsy (Profile 303712).
- 05 Dec 2018 New trial record